Amsterdam, the Netherlands – As part of the company’s commitment to innovation with an annual USD 600 million R&D spend in North America, Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will invest in a new R&D facility in Cleveland, Ohio, for its Computed Tomography and Advanced Molecular Imaging (CT/AMI) businesses.
The company will also invest to enhance its Cleveland facility to optimize its learning environment for the thousands of Philips field service engineers and for customers from across the globe, to meet the growing demand for technical and clinical training.
In conjunction with the decision to focus more on innovation and customer services, the Cleveland diagnostic imaging manufacturing operations, which currently make up less than 3% of the total global diagnostic imaging sales volume, will fully cease in the second half of 2018.
“Philips is well underway to step up the long-term success of its diagnostic imaging businesses,” said Rob Cascella, Chief Business Leader of the Diagnosis and Treatment businesses at Royal Philips. “With these investments, we will accelerate innovation in advanced diagnostic imaging at our Cleveland center of excellence and further enhance our customer services.”